Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,565
  • Shares Outstanding, K 27,461
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,460 K
  • 60-Month Beta 2.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.41
Trade CNSP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3900 +11.51%
on 08/20/21
1.7300 -10.40%
on 08/25/21
+0.0300 (+1.97%)
since 08/17/21
3-Month
1.3900 +11.51%
on 08/20/21
2.6800 -42.16%
on 06/29/21
-0.4500 (-22.50%)
since 06/17/21
52-Week
1.3900 +11.51%
on 08/20/21
4.4600 -65.25%
on 02/08/21
-0.4000 (-20.51%)
since 09/17/20

Most Recent Stories

More News
Dog Study May Offer Insight into How Gliomas Impact the Immune System

(MENAFN - Investor Brand Network) A recently conducted study has found that in comparison with low-grade gliomas, high-grade gliomas in canines contain more immune cells linked to suppressing immune response....

CNSP : 1.5500 (+1.31%)
CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook

/PRNewswire/ --  ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (CNS),...

CNSP : 1.5500 (+1.31%)
WPD Pharmaceuticals' Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical-stage pharmaceutical company, is pleased to announce that CNS Pharmaceuticals Inc. ("CNS") (NASDAQ:CNSP), the company...

WBIO.CN : 0.040 (+33.33%)
CNSP : 1.5500 (+1.31%)
CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM

/PRNewswire/ --  ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today...

CNSP : 1.5500 (+1.31%)
Thinking about buying stock in Transocean, CNS Pharmaceuticals, Bsquare, Iterum Therapeutics, or United Airlines?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIG, CNSP, BSQR, ITRM, and UAL.

BSQR : 2.47 (+0.82%)
CNSP : 1.5500 (+1.31%)
ITRM : 0.6256 (+3.75%)
UAL : 44.54 (+0.16%)
RIG : 3.35 (-3.46%)
Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027

PALM BEACH,  Fla., /PRNewswire/ -- Cancer is a foremost public health problem globally and is the second leading cause of death in the United States.  According to the National Brain Tumor Society,...

CNSP : 1.5500 (+1.31%)
MNKD : 4.53 (-0.66%)
ITRM : 0.6256 (+3.75%)
ONTX : 5.11 (+4.93%)
PFE : 43.89 (-1.30%)
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027

PALM BEACH,  Fla., /PRNewswire/ -- Glioblastoma multiforme (GBM) is one of the areas where the research & development investments are high and where global studies are growing. Everyone is looking to...

CNSP : 1.5500 (+1.31%)
AVXL : 17.63 (+3.89%)
BMY : 61.31 (+0.13%)
CLVS : 4.84 (+4.99%)
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

/PRNewswire/ -- (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous...

CNSP : 1.5500 (+1.31%)
WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidate clinical development program for...

WBIO.CN : 0.040 (+33.33%)
CNSP : 1.5500 (+1.31%)
CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index

/PRNewswire/ -- (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous...

CNSP : 1.5500 (+1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 1.6332
2nd Resistance Point 1.5966
1st Resistance Point 1.5733
Last Price 1.5500
1st Support Level 1.5134
2nd Support Level 1.4768
3rd Support Level 1.4535

See More

52-Week High 4.4600
Fibonacci 61.8% 3.2873
Fibonacci 50% 2.9250
Fibonacci 38.2% 2.5627
Last Price 1.5500
52-Week Low 1.3900

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar